Express Pharma

DRL launches lamotrigine orally disintegrating tablets in US

3

The therapeutic equivalent generic version of Lamictal ODT is available in 25 mg, 50 mg, 100 mg, and 200 mg

Dr Reddy’s Laboratories (DRL) has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg, a therapeutic equivalent generic version of Lamictal ODT (lamotrigine) Orally Disintegrating Tablets in the US market approved by the US Food & Drug Administration (USFDA).

The Lamictal ODT brand and generic had US sales of approximately $65.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

DRL’s lamotrigine orally disintegrating tablets 25 mg, 50 mg, 100 mg, and 200 mg are available in bottle count sizes of 30s.

Lamictal ODT is a registered trademark of GSK group of companies.

EP News Bureau

Comments are closed.